Free Newsletter
Post-marketing studies are the new norm
Have a funny feeling that post-marketing safety studies are more and more prevalent these days? Well, it's not just a feeling. The Tufts Center for the Study of Drug Development found that drugmakers are increasingly bound to study their products after they hit the market--and not only in the U.S., but in Europe and Japan, too.
Over the last decade, in fact, 75 percent of newly approved drugs in Europe and the U.S. and 50 percent in Japan came onto the market trailing a requirement for post-approval studies. "What used to be the exception is increasingly becoming the rule," the study's author said in a statement, adding that post-marketing studies may help identify safety issues earlier and help drugmakers serve patients better.
- check out the release from Tufts
- read the Boston Globe story
Related Articles:
Pharma drags feet on promised studies
GAO to probe FDA's post-market follow-up
Sponsors say post-marketing drug studies are a bust
Analysis shows post-marketing studies ignored
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: